The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 30, 2009
Filed:
Sep. 19, 2005
Emilio Kakkis, Novato, CA (US);
Daniel Oppenheimer, Castro Valley, CA (US);
Paul Fitzpatrick, Albany, CA (US);
Robert Heft, D.D.O., CA;
Alejandra Gamez, San Diego, CA (US);
Lin Wang, San Diego, CA (US);
Woomi Kim, Busan, KR;
Mary Straub, Malibu, CA (US);
Marianne Patch, San Diego, CA (US);
Raymond C. Stevens, La Jolla, CA (US);
Emilio Kakkis, Novato, CA (US);
Daniel Oppenheimer, Castro Valley, CA (US);
Paul Fitzpatrick, Albany, CA (US);
Robert Heft, D.D.O., CA;
Alejandra Gamez, San Diego, CA (US);
Lin Wang, San Diego, CA (US);
Woomi Kim, Busan, KR;
Mary Straub, Malibu, CA (US);
Marianne Patch, San Diego, CA (US);
Raymond C. Stevens, La Jolla, CA (US);
BioMarin Pharmaceutical Inc., Novato, CA (US);
The Scripps Research Institute, La Jolla, CA (US);
Abstract
The present invention pertains to the use of the protein phenylalanine ammonia-lyase, as well as the biologically-active derivatives of the said protein for preventing or treating diseases associated with a phenylalanine imbalance in a human or animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating a phenylalanine imbalance in vivo. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions. Finally, the present invention relates to processes for selecting more therapeutically-effective variants of said protein as well as to the selected variants themselves.